Table 2 Meta-analysis of the association between BRCA2 polymorphism and cancer risk

46

1.13 (1.03, 1.23)

<0.001

1.03 (0.99, 1.06)

0.642

1.07 (1.01, 1.13)

<0.001

1.12 (1.02, 1.23)

<0.001

30

1.11 (0.99, 1.23)

<0.001

1.01 (0.97, 1.05)

0.946

1.05 (0.98, 1.14)

<0.001

1.10 (0.98, 1.24)

<0.001

4

1.13 (0.92, 1.38)

0.587

1.14 (1.02, 1.27)

0.154

1.13 (1.02, 1.26)

0.384

1.06 (0.87, 1.30)

0.334

6

1.14 (0.83, 1.57)

0.065

1.01 (0.90, 1.12)

0.547

1.03 (0.92, 1.14)

0.236

1.23 (1.01, 1.43)

0.065

5

1.37 (1.08, 1.73)

0.580

1.05 (0.95, 1.17)

0.433

1.08 (0.96, 1.22)

0.531

1.35 (1.07, 1.70)

0.581

2

2.24 (0.23, 21.77)

0.026

1.06 (0.84, 1.33)

0.816

1.36 (1.10, 1.69)

0.440

2.19 (0.22, 21.72)

0.025

6

1.53 (0.99, 2.35)

0.454

1.02 (0.81, 1.27)

0.110

1.33 (0.81, 2.17)

<0.001

1.48 (0.85, 2.59)

0.170

34

1.07 (0.99, 1.16)

0.133

1.02 (0.99, 1.06)

0.605

1.03 (0.99, 1.07)

0.255

1.08 (1.00, 1.16)

0.038

4

1.15 (0.90, 1.48)

0.141

1.06 (0.91, 1.23)

0.888

1.06 (0.94, 1.20)

0.681

1.33 (1.01, 1.75)

0.660

11

0.98 (0.78, 1.24)

0.204

0.94 (0.86, 1.04)

0.419

0.96 (0.86, 1.07)

0.271

1.07 (0.86, 1.33)

0.063

27

1.18 (1.06, 1.32)

<0.001

1.04 (1.01, 1.08)

0.746

1.11 (1.03, 1.19)

<0.001

1.14 (1.01, 1.29)

<0.001

23

1.06 (0.94, 1.20)

0.288

1.04 (0.98, 1.10)

0.194

1.04 (0.98, 1.10)

0.277

1.16 (1.06, 1.26)

0.036

23

1.17 (1.03, 1.32)

<0.001

1.02 (0.98, 1.06)

0.917

1.06 (1.02, 1.10)

<0.001

1.09 (1.01, 1.17)

<0.001